Second Look at utilization of a closed-system transfer device (PhaSeal)

American Journal of Pharmacy Benefits

Volumn 3, Issue 6, 2011, Pages 311-318

  Thomas Carey, E ^a   Forrey, Ryan A ^b   Haughs, Douglas ^c   Jefferson, Dawn Moore ^d   Jorgenson, James A ^e   McMichael, Derek M ^d   Mulvaney, John M ^f   Spivey, Susan M ^g  

^a Swedish American Hospital   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c Bio Med QC   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e INDIANA UNIVERSITY HEALTH   (United States)

^f BUTLER UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASPERGILLUS; ASPERGILLUS BRASILIENSIS; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; CANDIDA ALBICANS; CLINICAL PROTOCOL; CLOSED SYSTEM TRANSFER DEVICE; COST CONTROL; DANGEROUS GOODS; DEVICE APPROVAL; DEVICE INFECTION; DRUG CONTROL; DRUG INDUSTRY; DRUG STERILITY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE UTILIZATION; INCUBATION TIME; INTERMETHOD COMPARISON; MEDICAL DEVICE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84859775992     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. McMichael D, Jefferson D, Carey E, Forrey R. Utility of the PhaSeal closed system drug transfer device. Am J Pharm Benefits. 2011;3(1):9-16.
2. Doloresco F, Fominaya C, Schumock GT, et al. Projecting future drug expenditures: 2011. Am J Health Syst Pharm. 2011;68(10):921-932.
3. US Pharmacopeia. USP<797> Guidebook to Pharmaceutical Compounding Sterile Product Preparations. Rockville, MD: United States Pharmacopeial Convention; 2008. http://www.usp.org/products/797Guidebook/. Accessed September 2, 2011.
4. National Institute for Occupational Safety and Health. NIOSH Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Atlanta, GA: NIOSH; September 2004. NIOSH publication 2004-165. http://www.cdc.gov/niosh/docs/2005-165/. Accessed September 2, 2011.
5. American Society of Health-System Pharmacists. ASHP guidelines for handling hazardous drugs [continuing education]. Am J Health Syst Pharm. 2006;63:1172-1191.
6. International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice: safe handling of cytotoxics. J Oncol Pharm Pract. 2007;13(suppl):1-81.
7. Jorgenson J, Spivey S, Au C, Canann D, Ritter H, Smith B. Contamination comparison of transfer devices intended for handling hazardous drugs. Hosp Pharm. 2008;43(9):723-727.
8. Spivey S, Connor T. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm. 2003;38(2):135-139.
9. Nygren O, Gustavsson B, Ström L, Eriksson R, Jarneborn L, Friberg A. Exposure to anti-cancer drugs during preparation and administration: investigation of an open and closed system. J Environ Monit. 2002;4(5):739-742.
10. ® Examples. 2nd ed. Cary, NC: SAS Institute; 2002.
11. ® System-A Practical Guide. Cary, NC: SAS Institute; 1995.
12. Sanchez-Rubio FJ. Extended stability of bortezomib. Hosp Pharm Europe. 2010;49:17-18.
13. Centers for Medicare & Medicaid Services. CMS Manual System. Publication 100-04 Medicare Claims Processing. Transmittal 1478. http://www.cms.hhs.gov/transmittals/downloads/R1478CP.pdf. Published January 1, 2008. Accessed October 18, 2011.
14. Vandenbroucke J. Economic Impact of the preparation scenario for cytotoxic drugs: an observational study. Eur J Hosp Pharm. 2008(5):37-42.